New Alzheimer’s Therapy Shows Promise in Reducing Amyloid Plaques in Brain

New Alzheimer’s Therapy Shows Promise in Reducing Amyloid Plaques in Brain
An investigational treatment for Alzheimer’s disease (AD) could be on the horizon, according to a study from researchers at Biogen and the University of Zurich. Aducanumab, a human monoclonal antibody, shows evidence of reducing Alzheimer’s amyloid plaques — the culprit behind AD-induced brain cell death. The treatment candidate is potentially the first of its kind, since

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.


  1. Dante J Marciani says:

    Apparently plaque has also a protective role by sequestering the neurotoxic amyloid beta oligomers; indeed, mentally functional individuals may have plaque as shown by postmortem examination. Yet, few mention that aducanumab recognizes that conformational epitope characteristic of neurotoxic Abeta oligomers only, quite possible interfering with their cytotoxic activity, regardless of plaque reduction. After all, most of the failing active and passive AD immunotherapy tested products were quite good in reducing plaque, but they failed in reversing or slowing down the loss of cognitive functions. That is the big difference between aducanumab and other agents. Of relevance is that this antibody is a natural one, i.e. it is produced by the body, a fact that strongly support the vaccine concept, assuming that such a vaccine is designed properly to mimic natural immune protection, and not to induce some odd immune response that would be most likely damaging.

Leave a Comment

Your email address will not be published. Required fields are marked *